Leptin
The 146-amino-acid adipose hormone discovered in 1994 that was supposed to cure obesity — and did, for the handful of people born without it. For everyone else, the story turned out to be leptin resistance, not leptin deficiency, and the therapeutic lesson has been much harder than the biology.
Leptin is the hormone fat cells make to tell the brain how much energy is stored. People born without it become severely obese and are transformed by leptin injections, which is why the 1994 discovery looked like a cure for obesity. It was not. Ordinary obesity is a high-leptin state, so adding more does nothing, and the one approved leptin drug (metreleptin / Myalept) is for lipodystrophy, a rare disease where the body cannot make fat tissue. There is no such thing as a leptin supplement.
What is Leptin?
Leptin is a four-helical-bundle cytokine-family hormone, product of the ob/LEP gene, secreted predominantly by white adipocytes in proportion to fat mass. The gene encodes a 167-amino-acid precursor, but a 21-residue signal peptide is cleaved during secretion, so the protein that actually circulates is 146 amino acids long (UniProt P41159); metreleptin, the recombinant drug, is that same chain plus an N-terminal methionine, making it 147 residues. It circulates at levels roughly proportional to body-fat content and signals the brain — principally the hypothalamic arcuate nucleus — about long-term energy reserves. Leptin deficiency in rare monogenic cases produces severe early-onset obesity that reverses dramatically with recombinant leptin replacement (metreleptin, FDA-approved as Myalept). Common obesity, in contrast, is a state of elevated leptin that the brain fails to respond to — the phenomenon collectively termed leptin resistance — and leptin replacement does not work in that context. The discovery of leptin in 1994 by the Friedman lab was one of the most dramatic events in metabolic medicine; the subsequent 30 years have been a case study in how a discovery of the problem does not automatically produce a therapy.
What Leptin Is Investigated For
Leptin is one of the most important endogenous peptides to understand but one of the least useful to administer. The FDA-approved indication (metreleptin, brand Myalept) is generalized lipodystrophy — a rare disorder where patients cannot produce normal adipose tissue and therefore have pathologically low leptin, with severe metabolic and fatty-liver consequences. Metreleptin reverses the metabolic picture dramatically in that population. For the much larger population of readers arriving at this page with questions about leptin and common obesity, the honest answer is that leptin replacement does not work there — obese patients already have elevated leptin, and the therapeutic problem is their brain's reduced responsiveness, not an absent signal. Low-dose leptin in the post-weight-loss state (Rosenbaum/Leibel work) has shown intriguing maintenance effects but has not become a therapy. This page is positioned as a biology reference and a reality-check on 'leptin supplements,' which are not a real category.
History & Discovery
The leptin story begins with the spontaneous ob/ob (obese) mouse mutation first described at Jackson Laboratory in 1950 and the db/db (diabetic) mutation described in 1966. Parabiosis experiments by Douglas Coleman in the 1970s established that ob/ob mice were missing a circulating factor that db/db mice could produce but not respond to — the first strong evidence for a blood-borne 'satiety hormone.' The ob gene itself remained elusive until Jeffrey Friedman's lab at Rockefeller positionally cloned it in 1994, publishing in Nature in December of that year. The product was named leptin, from Greek leptos (thin). The immediate preclinical confirmation came in 1995 — Halaas et al. showed recombinant leptin produced dramatic weight loss in ob/ob mice. The leptin receptor was cloned by Tartaglia and colleagues the same year. The first human cases of congenital leptin deficiency, identified by the Farooqi/O'Rahilly group in Cambridge in 1997, produced the extraordinary 1999 NEJM paper demonstrating reversal of severe obesity in a child given recombinant leptin. At this point the field believed it had a blockbuster coming. The Heymsfield 1999 JAMA trial of recombinant leptin in common obesity was the cold shower — doses far above physiologic produced only modest weight loss and substantial injection-site reactions, and the drug development program for common obesity effectively ended. The indication that did translate was generalized lipodystrophy, where leptin levels are pathologically low due to absence of adipose tissue — Oral et al. 2002 NEJM demonstrated dramatic reversal of the associated metabolic syndrome, and metreleptin (Myalept) received FDA approval in 2014 for that narrow indication. The lipodystrophy indication sustains the commercial product; the rest of the field has moved toward understanding leptin resistance rather than trying to overcome it with replacement.
How It Works
Leptin is the fat-mass thermostat signal. Fat cells make it in proportion to how much fat you have, and it tells the brain 'we have enough stored energy — you can stop driving appetite.' In rare people born without leptin, the brain thinks it's starving even at enormous body weight, and giving them leptin fixes it. In common obesity, the problem isn't that leptin is missing — it's that the brain has tuned out the signal. Adding more leptin to a tuned-out brain doesn't work, which is why the 'leptin cure' that seemed obvious in 1995 turned out not to be.
Leptin signals through the long-form leptin receptor (LEPR-B / ObRb), a class I cytokine receptor expressed on hypothalamic arcuate nucleus neurons including POMC/CART (anorexigenic) and NPY/AgRP (orexigenic) populations. Leptin binding drives JAK2 phosphorylation and STAT3 activation in POMC neurons, increasing transcription of POMC and its downstream cleavage products (α-MSH) that engage MC4R in the paraventricular nucleus to suppress food intake and increase energy expenditure. In NPY/AgRP neurons, leptin inhibits NPY release. The net output of leptin signaling is anorexigenic and thermogenic. Leptin resistance is best understood as a reduction in signal throughput rather than a single-step defect. SOCS3 (suppressor of cytokine signaling 3) is transcriptionally induced by STAT3 itself, providing negative feedback; chronic elevated leptin drives elevated SOCS3, which inhibits further JAK2-STAT3 signaling. PTP1B dephosphorylates JAK2 and provides a parallel negative-feedback loop. Saturable transport of leptin across the blood-brain barrier appears to have reduced capacity in obese states, so CSF leptin does not rise in proportion to serum leptin. Mediobasal hypothalamic inflammation (activated microglia, elevated IKKβ/NF-κB signaling) contributes. Downstream defects in the melanocortin pathway — particularly MC4R signaling — can produce leptin-resistance-like phenotypes independent of upstream leptin signaling itself, which is the rationale for setmelanotide as a treatment for specific monogenic obesity forms. Two lines of work since 2019 have pushed this picture further than the standard SOCS3/PTP1B account. The first identified mTOR as a specific pathogenic node: leptin treatment lowers circulating leucine and methionine, chronic mTOR activation in POMC neurons blunts leptin signalling, and rapamycin restores leptin sensitivity in diet-induced obese mice but not in mice whose leptin or melanocortin signalling is already broken. On that evidence, increased mTOR activity in POMC neurons is described as necessary and sufficient for leptin resistance in those mice. The second inverts the therapeutic logic entirely. Work from the Scherer laboratory argues that hyperleptinemia is itself a driver of metabolic disease, and that partially lowering plasma leptin with a neutralising antibody restores hypothalamic leptin sensitivity and reduces weight gain — the opposite prescription to leptin replacement. Both remain rodent findings, and neither has been tested as a therapy in humans, but together with impaired autophagy and peripheral (non-hypothalamic) leptin resistance they are now part of any current account of the phenomenon.
Evidence Snapshot
Human Clinical Evidence
Strong for the rare-disease indications: congenital leptin deficiency responds dramatically to replacement (Farooqi 1999 NEJM), and generalized lipodystrophy responds to metreleptin (Oral 2002 NEJM and follow-up), with a 2019 NIH study extending the same pattern to partial lipodystrophy and 2025-2026 real-world data (the European Lipodystrophy Registry, Japanese post-marketing surveillance out to seven years) confirming durability. Moderate and under-appreciated for hypothalamic amenorrhea: a 36-week randomized, double-blind, placebo-controlled trial of metreleptin restored menstruation and corrected gonadal, thyroid, growth-hormone and adrenal axis abnormalities. Weak for common obesity — but the usual shorthand that the Heymsfield 1999 JAMA trial was a negative study is not what that paper reported. It found a dose-response for weight and fat loss and concluded that further research was warranted; what killed the indication was the size of the effect relative to the dose, cohorts of 6 to 8 patients at the high doses, and standard deviations larger than the means. Emerging for post-weight-loss maintenance (Rosenbaum/Leibel).
Animal / Preclinical
Extensive. Leptin biology was characterized through the ob/ob (leptin-null) and db/db (leptin-receptor-null) mouse models over decades. Halaas 1995 Science showed dramatic weight loss with recombinant leptin in ob/ob mice — the original preclinical demonstration that ran ahead of the subsequent human disappointment in common obesity.
Mechanistic Rationale
Strong. Leptin signaling through JAK2-STAT3 and the arcuate melanocortin pathway is one of the best-characterized endocrine axes. The mechanistic story explains why common-obesity leptin replacement failed — the limitation was never on the leptin-signal side.
Research Gaps & Open Questions
What the current literature has not yet settled about Leptin:
- 01Whether low-dose leptin replacement can be developed as a post-weight-loss maintenance therapy to prevent regain. The gap is commercial rather than untested: academic placebo-controlled trials of the hypothesis were completed (NCT01155180, NCT00050791) and no sponsor took it further.
- 02The true mechanism of leptin resistance in common obesity — multiple proposed pathways (SOCS3, PTP1B, BBB transport, hypothalamic inflammation, impaired autophagy, mTOR activation in POMC neurons, peripheral as distinct from hypothalamic resistance, and downstream MC4R defects) likely each contribute, but relative weights remain unresolved.
- 03Whether the leptin-resistance problem should be attacked by adding leptin signal at all. Rodent work from 2019 onward argues that hyperleptinemia is itself pathogenic and that partially lowering leptin restores hypothalamic sensitivity — the opposite intervention. No human trial has tested leptin reduction as a weight-loss strategy.
- 04Whether pharmacologic agents that improve leptin sensitivity (SOCS3 inhibitors, PTP1B inhibitors, agents targeting hypothalamic inflammation) can produce clinically meaningful weight loss in common obesity.
- 05Whether the lymphoma signal in metreleptin-treated lipodystrophy patients reflects drug effect, underlying disease risk, or both. A 2025 pharmacovigilance review moved the balance toward disease — most reported lymphomas were in patients who had never received metreleptin — but it is an observational analysis of a very small case set, not a resolution.
- 06The role of partial lipodystrophy as a metreleptin indication — approved in the EU, not in the US, with ongoing evidence development.
- 07Long-term neutralizing-antibody outcomes, and whether the immunogenicity problem is better solved by a different modality than by engineering a leptin variant. The field has largely taken the second route: mibavademab (REGN4461) is a leptin-receptor agonist antibody that activates LEPR with or without leptin present, and a Phase 3 study of patients switching from metreleptin to mibavademab in generalized lipodystrophy completed in July 2026.
- 08Whether specific genetic subtypes of common obesity (MC4R-deficient, leptin-signaling-pathway polymorphisms) respond differently to leptin replacement or to melanocortin agonists like setmelanotide.
Forms & Administration
Metreleptin (Myalept) is recombinant methionyl human leptin produced in E. coli, supplied as a lyophilized powder for subcutaneous injection. It is administered once daily, typically at the same time each day, with dose titrated to clinical response in lipodystrophy. Access in the US is restricted to prescribers and patients enrolled in the Myalept REMS program because of the antibody-formation and lymphoma signals. It is not available in compounded-peptide formularies and is not appropriate for self-administration in common obesity. Research-grade recombinant leptin exists for preclinical and investigational-use work but is not a legitimate therapeutic source.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Metreleptin for generalized lipodystrophy: weight-based starting dose of 0.06 mg/kg/day SC for patients weighing ≤40 kg, or fixed-dose 2.5 mg/day for males and 5 mg/day for females weighing >40 kg. Dose may be titrated up to 0.13 mg/kg/day (low weight) or 10 mg/day (higher weight) based on clinical response and tolerability. Research-use low-dose leptin (the Rosenbaum/Leibel post-weight-loss-maintenance paradigm) is often misquoted. That protocol started at 0.08 mg per kg of fat mass per dose in men and 0.14 mg/kg fat mass per dose in women, titrated weekly to restore 8 a.m. leptin to the pre-weight-loss level; expressed the way a label would, the mean total daily dose worked out to 0.068 mg/kg of body mass, with a range across subjects of 0.019 to 0.121 mg/kg/day.
Frequency
Once-daily subcutaneous administration at a consistent time of day is standard for the approved indication, and the label explicitly allows any time of day without regard to meals. Metreleptin's half-life after single subcutaneous doses in healthy subjects is 3.8 to 4.7 hours, which is short relative to the dosing interval; once-daily dosing is nonetheless clinically adequate in lipodystrophy. The research protocols in weight-reduced subjects are the exception — those dosed twice daily, at 8 a.m. and 8 p.m., because the goal was to reproduce a physiologic leptin concentration rather than to replace a missing hormone.
Timing Considerations
Time of day
Once daily at a consistent time — morning is common in most protocols; bedtime is used when daytime hypoglycemia is a concern in diabetic lipodystrophy patients.
Relative to meals
Not meal-timed in a clinically meaningful sense.
Relative to exercise
Not tied to exercise timing.
Consistency matters more than specific time of day. The pharmacokinetic profile of metreleptin does not produce meaningful meal-timing benefits.
Cycle Length
Indefinite for generalized lipodystrophy — metreleptin is a chronic replacement therapy, not a cycled intervention. Treatment typically continues lifelong pending alternative therapies or resolution of lipodystrophy (which essentially does not occur with current treatment options).
Protocol Notes
Metreleptin initiation in lipodystrophy patients routinely requires substantial reductions in insulin and oral antihyperglycemic therapy because of the improvement in insulin sensitivity — hypoglycemia in the first weeks is a real and anticipated issue that prescribers manage proactively. Injection-site rotation matters. Anti-metreleptin neutralizing antibodies develop in some patients over time and can reduce efficacy or, rarely, cross-react with endogenous leptin to produce a functional leptin deficiency syndrome — this is a key reason for the REMS program. There is no legitimate compounded-peptide pathway for leptin; the molecule requires Myalept as the commercial source. Practical handling detail: each vial holds an 11.3 mg lyophilized cake reconstituted with 2.2 mL of diluent to 5 mg/mL. Bacteriostatic water is the usual diluent, but it is preserved with benzyl alcohol, so the label calls for preservative-free sterile water instead in neonates and infants. Low-dose leptin in the post-weight-loss state remains a research use, not an approved indication. The Rosenbaum/Leibel protocols used specific dosing to restore pre-weight-loss leptin levels and documented improvements in thyroid axis, sympathetic nervous system tone, and skeletal muscle efficiency — results consistent with leptin's role as an adiposity-proportional energy-reserve signal. No commercial therapy has emerged from this line of work.
Metreleptin is a REMS-controlled prescription medication for a specific rare indication. Nothing on this page constitutes a suggested protocol for common-obesity self-use — there is no such thing as effective leptin replacement in common obesity.
Timeline of Effects
Onset
Serum metabolic effects (triglyceride reduction, glucose improvement) begin within the first 1–4 weeks of metreleptin therapy in lipodystrophy. Appetite suppression, when it occurs, is often evident within days at full dose.
Peak Effect
Peak metabolic response in lipodystrophy typically develops over 3–6 months of continuous therapy. Hepatic fat content (MRI-PDFF) responses often lag the glucose and triglyceride improvements.
After Discontinuation
Metabolic decompensation typically returns within weeks of discontinuation in lipodystrophy patients — this is a chronic replacement therapy analogous to insulin, not a time-limited intervention. In research-use low-dose leptin for post-weight-loss maintenance, the reported physiologic effects reverse on discontinuation.
Monitoring & Measurement
Bloodwork & Labs
- •Serum leptin (ELISA — level tracks fat mass; interpretation requires body-composition context)
- •Soluble leptin receptor (sOB-R; free-leptin index calculations in research use)
- •Neutralizing anti-metreleptin antibodies (REMS program testing on metreleptin therapy)
- •Fasting glucose, HbA1c, fasting lipid panel (primary efficacy endpoints in lipodystrophy)
- •ALT/AST and MRI-PDFF for hepatic steatosis monitoring in lipodystrophy
Functional & Performance Tests
- •DEXA body composition — contextualizes serum leptin and tracks the fat-mass-proportional baseline
- •MRI fat-depot quantification in lipodystrophy characterization
When to Test
For lipodystrophy patients on metreleptin: baseline biomarker panel, 4–12 weeks post-initiation, then every 3–6 months during stable therapy. Neutralizing-antibody testing per REMS schedule. For research use or diagnostic leptin levels: fasting morning sample with standard serum handling.
Interpretation & Notes
Serum leptin has a clinically meaningful role primarily in diagnosing suspected monogenic leptin deficiency (where levels are undetectable or near-zero despite substantial adiposity) and in characterizing lipodystrophy (where levels are inappropriately low for the apparent body habitus). In common-obesity evaluation, elevated leptin is the expected finding and rarely changes management. Serum-leptin ELISAs from different manufacturers produce meaningfully different absolute values — results should be interpreted within the reporting lab's reference range and ideally tracked using the same assay platform over time. This is documented rather than theoretical: a 150-patient comparison of three common leptin assays found them not interchangeable, and no reliable cut point emerged for selecting metreleptin responders in partial lipodystrophy (ROC AUC 0.61 to 0.65, none significant).
Common Questions
Can I take leptin to lose weight?
No, with essentially no exceptions outside specific rare deficiency states. Common obesity is a high-leptin state — obese patients have several-fold elevated serum leptin compared to lean controls. Adding more leptin does not produce weight loss because the brain is already not responding to the levels that are there. The 1999 Heymsfield JAMA trial of recombinant leptin in common obesity showed small effects at heroic doses with substantial injection-site reactions and was effectively a dead-end for the common-obesity indication.
What is leptin resistance, really?
It's an umbrella term for reduced responsiveness of hypothalamic leptin signaling despite elevated circulating leptin. The mechanisms are plural and incompletely resolved: SOCS3 upregulation in leptin-signaling neurons, PTP1B-mediated negative feedback on JAK2-STAT3, impaired leptin transport across the blood-brain barrier, ER stress, inflammation in the mediobasal hypothalamus, and downstream defects in the melanocortin pathway (MC4R signaling) that leptin normally engages. It is not 'broken receptors' in the simple sense — it is a multi-layered reduction in signal throughput.
What is metreleptin / Myalept used for?
Metreleptin is recombinant methionyl human leptin. The US label (Myalept, Chiesi) indicates it as an adjunct to diet, as replacement therapy, to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. The label also carries explicit Limitations of Use: safety and effectiveness have not been established for partial lipodystrophy or for liver disease including NASH, and it is not indicated for HIV-related lipodystrophy or for metabolic disease without concurrent evidence of generalized lipodystrophy. It is not approved for common obesity. In the US it requires enrollment in a REMS program because of risks including anti-metreleptin neutralizing antibodies and reported T-cell lymphoma.
Does metreleptin work for partial lipodystrophy?
It depends on where you are. The EU label (Myalepta, Chiesi, marketing authorisation 30 July 2018, EMEA/H/C/004218) covers confirmed familial or acquired partial lipodystrophy in adults and children 12 and over, but only for those in whom standard treatments have failed to achieve adequate metabolic control. The US label does not: the FDA explicitly lists partial lipodystrophy under Limitations of Use as not established. The evidence behind the EU position is real but narrower than the generalized-lipodystrophy data — a 12-month NIH study of patients with partial lipodystrophy and leptin below 12.0 ng/mL found HbA1c fell 0.6%, fasting triglycerides 20.8% and liver volume 13.4%, with larger effects in the subgroup that started with worse metabolic disease. Part of the reason the indication has not broadened is that baseline leptin does not reliably predict who will respond in partial lipodystrophy.
Is metreleptin the leptin drug for HIV-associated lipodystrophy?
No, and the label says so directly: Myalept is not indicated for HIV-related lipodystrophy. The peptide used in that setting is tesamorelin (Egrifta), a GHRH analog that reduces visceral fat in HIV-associated lipodystrophy and works through an entirely different axis. The two get conflated because both are peptides for a condition with the word lipodystrophy in it.
Can intermittent fasting or keto 'reset' leptin resistance?
Weight loss of any kind lowers serum leptin, which is a consequence rather than a mechanism. Whether specific dietary patterns produce leptin-resistance improvement beyond the fat-mass reduction is not well established — the serum-leptin decline tracks adiposity more than intervention type. The marketing language around leptin 'resets' runs well ahead of what the mechanistic data support.
Who Leptin Is NOT For
- •General obesity not associated with congenital leptin deficiency — one of only two contraindications on the US label. Metreleptin has not been shown effective here, and neutralizing antibodies have been reported in obese patients who received it.
- •Prior severe hypersensitivity reaction to metreleptin or any product component — the label's other contraindication. Reported reactions include anaphylaxis, urticaria and generalized rash.
- •Significant hematologic abnormalities (leukopenia, neutropenia, bone-marrow abnormalities, lymphoma, lymphadenopathy) or acquired generalized lipodystrophy — not a contraindication on the label, but the boxed warning asks prescribers to weigh benefits and risks carefully in these patients because of the T-cell lymphoma reports.
- •Autoimmune disease — again a warning rather than a contraindication: progression of autoimmune disorders has been observed during metreleptin treatment.
- •Pregnancy — not a labeled contraindication. Human data are insufficient to evaluate risk, a mouse study showed prolonged gestation and dystocia with maternal deaths, and there is an open pregnancy exposure registry; treatment decisions are individual rather than categorical.
Drug & Supplement Interactions
Metreleptin's main interaction space is insulin and oral antihyperglycemic medications — improvement in insulin sensitivity on metreleptin therapy in lipodystrophy patients frequently requires substantial reductions in these agents, and failure to anticipate this produces hypoglycemia. Prescribers routinely begin tapering insulin on day one of metreleptin initiation in previously insulin-requiring lipodystrophy patients. Leptin signaling intersects with several hypothalamic-pituitary axes (gonadal, thyroid, adrenal), so metreleptin can modestly alter thyroid and reproductive hormone levels, which sometimes affects dosing of thyroid replacement or hormonal contraception. The CYP450 question is more concrete than it is usually presented. No formal interaction studies were done, but the label states that leptin is a cytokine with the potential to alter the formation of CYP450 enzymes, and it asks prescribers to take that into account for substrates with a narrow therapeutic index whose dose is individually adjusted. It names the practical cases: monitor effect for warfarin, monitor drug concentration for cyclosporine and theophylline, and consider oral contraceptives. Critically, the guidance applies on discontinuation as well as initiation, which is the step most likely to be missed. There is no clinically important interaction between metreleptin and GLP-1 agonists, though the two are rarely combined because their indication spaces don't overlap. Concurrent metreleptin and rhGH use has not been systematically studied.
Safety Profile
Common Side Effects
Cautions
- • REMS program enrollment required in the US because of anti-metreleptin neutralizing antibody risk
- • Boxed warning for T-cell lymphoma: three cases were reported in the metreleptin lipodystrophy program, all in patients with acquired generalized lipodystrophy, and the label says a causal relationship has not been established
- • Autoimmune disorder progression has been observed on metreleptin; the label asks prescribers to weigh benefits and risks in patients with autoimmune disease
- • Insulin dose reduction often required at initiation; hypoglycemia is a real early risk in diabetic lipodystrophy patients
- • Has not been shown safe or effective in common obesity despite marketing framing
- • Pregnancy — the current label uses the PLLR format, not a letter category, and states that pharmacovigilance reports are insufficient to evaluate drug-associated risk; a pregnancy exposure registry is open
What We Don't Know
Whether sub-physiologic-dose leptin replacement in the post-weight-loss state can durably prevent weight regain in common-obesity patients remains an open and interesting question. Academic placebo-controlled trials of exactly that hypothesis were run and completed (Beth Israel Deaconess, NCT01155180; Rockefeller, NCT00050791), but no commercial development program followed them. The lymphoma question has moved: a 2025 pharmacovigilance review and literature search found 17 lymphomas across 16 lipodystrophy patients, of which 12 were in people who had never received metreleptin, and all nine T-cell lymphomas occurred in acquired generalized lipodystrophy — the authors concluded the association tracks the underlying disease rather than the drug, while noting a contributory role cannot be excluded.
Legal Status
United States
Metreleptin (Myalept) was approved by the FDA on 24 February 2014 under BLA 125390, on priority review, as an adjunct to diet and as replacement therapy for the complications of leptin deficiency in congenital or acquired generalized lipodystrophy. The application is now held by Chiesi, which acquired Amryt in 2023, and the product remains marketed. The label's Limitations of Use are explicit that it is not established for partial lipodystrophy or for liver disease including NASH, and not indicated for HIV-related lipodystrophy or for metabolic disease without concurrent generalized lipodystrophy; it is contraindicated in general obesity not associated with congenital leptin deficiency. US access requires enrollment of both prescriber and patient in the Myalept REMS program because of the neutralizing-antibody and lymphoma risks in the boxed warning. It is not available through compounded pharmacies, and it was not among the six peptide bulk substances covered by the HHS 503A enforcement discretion policy of 28 October 2026.
International
The EU indication is genuinely broader, but with gates the usual summary leaves out. Myalepta (EMEA/H/C/004218, marketing authorisation granted 30 July 2018, holder Chiesi Farmaceutici, orphan designation 17 July 2012) is authorised under exceptional circumstances as an adjunct to diet and replacement therapy for the complications of leptin deficiency in confirmed congenital generalised lipodystrophy (Berardinelli-Seip) or acquired generalised lipodystrophy (Lawrence) in adults and children 2 years and above, and in confirmed familial partial or acquired partial lipodystrophy (Barraquer-Simons) in adults and children 12 years and above for whom standard treatments have failed to achieve adequate metabolic control. Japan has approved metreleptin since 2013 and has published eight years of post-marketing surveillance covering 48 patients. Access elsewhere varies.
Sports & Competition
Leptin and metreleptin are not named on the WADA Prohibited List (the 2026 list, or the 2027 list that takes effect January 1, 2027). Metreleptin is an approved medicine, so WADA's S0 'non-approved substances' category does not apply to it. Its use is not a recognized performance-enhancement strategy. The practical reality is that access is restricted to the lipodystrophy population, so sports-doping use is essentially nonexistent.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Leptin supplements help you lose weight.
Reality
There is no such thing. Oral leptin would be destroyed by digestion (it's a protein), and 'leptin-related' supplements sold in the wellness market either contain no leptin or contain unrelated compounds marketed with the word. Even if bioavailable leptin could be taken, it would not work in common obesity because the problem is leptin resistance, not leptin deficiency — obese patients already have elevated endogenous leptin.
Myth
Leptin resistance is just broken leptin receptors.
Reality
Leptin-receptor-null genetic disease (db/db mice, LEPR mutations in humans) exists and produces severe obesity, but that is not what 'leptin resistance' refers to in common obesity. Common-obesity leptin resistance is a multi-step reduction in signal throughput — SOCS3-mediated negative feedback, PTP1B-mediated dephosphorylation, reduced BBB leptin transport, hypothalamic inflammation, and downstream melanocortin-pathway attenuation. The receptors themselves are usually intact.
Myth
Intermittent fasting or keto fixes leptin resistance.
Reality
Fasting and ketogenic diets lower serum leptin because they reduce fat mass, which is the known regulator of leptin production. Whether they improve leptin-signal responsiveness beyond the effect of fat-mass reduction is not well established. Most of the mechanistic signal is explained by adiposity reduction, not by any intervention-specific 'leptin reset' effect that the marketing language implies.
Myth
Higher leptin is always a bad sign.
Reality
Serum leptin is a marker of fat mass, not a causal driver of disease in most individuals. High leptin in obesity reflects the fat mass that produced it. Low leptin in lipodystrophy or severe caloric restriction is the pathologic state that responds to replacement. The clinical question is usually about the adiposity the leptin level reflects, not about leptin itself.
Myth
Metreleptin is the peptide used for HIV-associated lipodystrophy.
Reality
It is not, and the Myalept label says so in its Limitations of Use: the drug is not indicated for HIV-related lipodystrophy. The peptide used there is tesamorelin, a GHRH analog that reduces visceral adipose tissue in HIV-associated lipodystrophy and works through the growth-hormone axis rather than by replacing a missing hormone. The two are confused because the word lipodystrophy covers both, but the underlying problem is opposite in kind: generalized lipodystrophy is a leptin-deficient state, while HIV-associated fat redistribution is not.
Myth
Metreleptin is a weight-loss drug for common obesity.
Reality
Metreleptin is approved only for generalized lipodystrophy — a rare condition where patients do not produce adequate adipose tissue and therefore have pathologically low leptin. In common obesity, leptin is already elevated and metreleptin has not shown meaningful efficacy. The 1999 Heymsfield JAMA trial effectively ended the common-obesity development program over two decades ago.
Published Research
23 studiesPostmarketing Surveillance of the Safety and Effectiveness of Metreleptin in Patients with Lipodystrophy in Japan
Epidemiological and clinical data from the European Lipodystrophy Registry
Leptin and leptin resistance in obesity: current evidence, mechanisms and future directions
A real-world pharmacovigilance assessment and literature review of lymphoma development in lipodystrophy
The best available answer to the page's oldest open question. Combining the marketing authorisation holder's 11-year global safety database with a literature search, the authors assembled 17 lymphomas across 16 lipodystrophy patients. Twelve occurred in patients who had never received metreleptin; five were in four treated patients. All nine T-cell lymphomas arose in acquired generalized lipodystrophy. Their conclusion is that lymphoma tracks the pathophysiology underlying lipodystrophy rather than the drug, while allowing that a contributory role cannot be excluded.
A cellular and molecular basis of leptin resistance
Preclinical, randomized phase 1, and compassionate use evaluation of REGN4461, a leptin receptor agonist antibody for leptin deficiency
Endogenous Leptin Concentrations Poorly Predict Metreleptin Response in Patients With Partial Lipodystrophy
Partial Leptin Reduction as an Insulin Sensitization and Weight Loss Strategy
Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy
Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy
Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy
Leptin is an effective treatment for hypothalamic amenorrhea
Chou et al. 2011 PNAS — the randomized, double-blind, placebo-controlled trial that moved hypothalamic amenorrhea from hypothesis to demonstrated leptin-responsive state. Over 36 weeks, metreleptin at replacement doses restored menstruation and corrected abnormalities across the gonadal, thyroid, growth-hormone and adrenal axes. It is the strongest human evidence for leptin as an energy-availability signal to the reproductive axis, and it has never translated into an approved indication.
Adipokines as novel biomarkers and regulators of the metabolic syndrome
Obesity and leptin resistance: distinguishing cause from effect (Myers et al., Trends Endocrinol Metab 2010)
Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight
Rosenbaum/Leibel et al. 2005 JCI — showed that sub-replacement-dose leptin reverses several of the adaptations to weight loss that drive regain. A key reference for the post-weight-loss-maintenance hypothesis that has never translated into a drug program.
Recombinant human leptin in women with hypothalamic amenorrhea
Leptin-replacement therapy for lipodystrophy
Oral et al. 2002 NEJM — demonstrated dramatic metabolic improvements with leptin replacement in patients with severe lipodystrophy, establishing the indication that ultimately became the FDA approval for metreleptin.
Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial
Heymsfield et al. 1999 JAMA — the trial usually described as the one that ended leptin's run at common obesity, though that is not what it reported. In 54 lean and 73 obese adults given daily subcutaneous recombinant leptin at 0 to 0.30 mg/kg, weight loss rose with dose (P = .02 at 4 weeks; P = .01 among obese subjects at 24 weeks), mean changes ran from -0.4 kg on placebo to -1.9 kg at 0.1 mg/kg by week 4 and reached -7.1 kg at 0.30 mg/kg by week 24, and injection-site reactions were mild to moderate. The authors concluded that further research was warranted. What actually sank the indication was the dose required, cohorts of 6 and 8 patients at the top doses, and standard deviations (5.4 and 8.5 kg) wider than the means.
Effects of recombinant leptin therapy in a child with congenital leptin deficiency
Farooqi et al. 1999 NEJM — the dramatic demonstration that recombinant leptin reverses obesity in congenital leptin deficiency. One of the most compelling single-case therapeutic demonstrations in metabolic medicine.
Congenital leptin deficiency is associated with severe early-onset obesity in humans
Identification and expression cloning of a leptin receptor, OB-R
Positional cloning of the mouse obese gene and its human homologue
Zhang et al. 1994 Nature — the original cloning of the ob gene from the leptin-deficient mouse, by Jeffrey Friedman's lab at Rockefeller. One of the landmark papers in late-20th-century endocrinology.
Weight-reducing effects of the plasma protein encoded by the obese gene
Halaas et al. 1995 Science — demonstrated that recombinant leptin produces dramatic weight loss in ob/ob mice (leptin-deficient) but only modest effects in wild-type mice, foreshadowing the common-obesity disappointment that came four years later.
Quick Facts
- Class
- Adipokine
- Tier
- A
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Nov 2026
- Citations
- 23PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.